ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.322,59
0,91%
S&P 500
5.969,34
0,35%
Dow Jones
44.296,51
0,97%
Euro vs US Dollar
1,0418
0,00%
Bitcoin
98.025,89
-1,02%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE

  6. Molecular Partners Ag (0QXX) Börsenkurse

Molecular Partners Ag

Molecular Partners Ag (0QXX)

LSE
25,20
0,00
(0,00%)
Geschlossen 23 November 5:30PM
Verzögert um 15 Minuten

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
25,20
Gebot
0,00
Fragen
0,00
Volumen
113
0,00 Tagesbereich 0,00
25,20 52-Wochen-Bereich 25,20
Marktkapitalisierung
916,121M
Handelsende
25,20
Handelsbeginn
-
Letzte Trade
113
@
4.845
(O)
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
420
Ausgegebene Aktien
36.354.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-14,78
Gewinn pro Aktie (EPS)
-1,71
Erlöse
7,04M
Nettogewinn
-61,98M

Über Molecular Partners Ag

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
www.molecularpartners.com
Hauptsitz
Schlieren, Che
Gegründet
-
Molecular Partners Ag is listed in the Pharmaceutical Preparations sector of the Londoner Börse with ticker 0QXX. The last closing price for Molecular Partners was CHF25,20. Over the last year, Molecular Partners shares have traded in a share price range of CHF 25,20 to CHF 25,20.

Molecular Partners currently has 36.354.000 shares in issue. The market capitalisation of Molecular Partners is CHF916,12 million. Molecular Partners has a price to earnings ratio (PE ratio) of -14.78.

0QXX Neueste Nachrichten

Weitere Nachrichten

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024 Preclinical proof-of-concept data supports the...

07 November 2024
UK Regulatory

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall...

05 November 2024
UK Regulatory

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going Radio-DARPin Therapy...

31 Oktober 2024
UK Regulatory

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

Molecular Partners Announces Pricing of $20 Million Underwritten Offering ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art...

25 Oktober 2024
UK Regulatory

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024 Dose-dependent efficacy observed with...

22 Oktober 2024
UK Regulatory

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics Under the revised agreement, both companies will co-develop four Radio-DARPin programs;...

22 Oktober 2024
UK Regulatory

Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting

Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting Preclinical proof-of-concept data supports CD3 Switch-DARPin platform for T cell engagers with enhanced...

04 Oktober 2024
UK Regulatory

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM...

27 September 2024
UK Regulatory

Molecular Partners Reports H1 2024 Corporate Highlights and Financials

Molecular Partners Reports H1 2024 Corporate Highlights and Financials First Radio-DARPin Therapy (RDT) candidate MP0712 nominated; supporting preclinical package presented at SNMMI; initial...

26 August 2024
UK Regulatory

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of...

14 Juni 2024
UK Regulatory
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10025.225.225.248025.2DE
40025.225.225.268825.2DE
120025.225.225.242025.2DE
260025.225.225.240425.2DE
520025.225.225.2165125.2DE
1560025.225.225.21017725.2DE
2600025.225.225.2725525.2DE

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
SCGLSealand Capital Galaxy Limited
0,21p
(50,00%)
219,35M
PPSProton Motor Power Systems Plc
0,175p
(40,00%)
3,79M
PXCPhoenix Copper Limited
7,00p
(37,25%)
5,13M
SLFRSlf Realisation Fund Limited
1,49p
(29,57%)
827,89k
NWORNational World Plc
19,00p
(26,67%)
2,74M
WEBWebis Holdings Plc
0,125p
(-68,75%)
28,06M
HEMOHemogenyx Pharmaceuticals Plc
1,15p
(-24,59%)
102,87M
AMGOAmigo Holdings Plc
0,525p
(-16,67%)
15,73M
PLAZPlaza Centers N.v.
25,00p
(-16,67%)
2k
AURRAurrigo International Plc
52,50p
(-15,32%)
66,25k
NTVONativo Resources Plc
0,0026p
(13,04%)
4,92B
CPXCap-xx Limited
0,14p
(9,80%)
395,59M
NTOGNostra Terra Oil And Gas Company Plc
0,02275p
(-4,21%)
394,31M
VELAVela Technologies Plc
0,007p
(-6,67%)
336,14M
MSMNMosman Oil And Gas Limited
0,0395p
(-3,66%)
314,18M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

LSE
0QXX
Molecular Partners
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten